Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3922]

Quality of life results from pembrolizumab vs chemotherapy in gastric or...

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of...

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Highlights from ESMO 2019

Prof Josep Tabernero - ESMO President

Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal...

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative...

Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO...

Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )

More from ecancer